Immunopurification of adenomatous polyposis coli (APC) proteins

Kerryn L Elliott,Bruno Catimel,Nicole L Church,Janine L Coates,Antony W Burgess,Meredith J Layton,Maree C Faux
DOI: https://doi.org/10.1186/1756-0500-6-429
2013-10-25
BMC Research Notes
Abstract:Abstract Background The adenomatous polyposis coli ( APC ) tumour suppressor gene encodes a 2843 residue (310 kDa) protein. APC is a multifunctional protein involved in the regulation of β-catenin/Wnt signalling, cytoskeletal dynamics and cell adhesion. APC mutations occur in most colorectal cancers and typically result in truncation of the C-terminal half of the protein. Results In order to investigate the biophysical properties of APC, we have generated a set of monoclonal antibodies which enable purification of recombinant forms of APC. Here we describe the characterisation of these anti-APC monoclonal antibodies (APC-NT) that specifically recognise endogenous APC both in solution and in fixed cells. Full-length APC(1–2843) and cancer-associated, truncated APC proteins, APC(1–1638) and APC(1–1311) were produced in Sf9 insect cells. Conclusions Recombinant APC proteins were purified using a two-step affinity approach using our APC-NT antibodies. The purification of APC proteins provides the basis for detailed structure/function analyses of full-length, cancer-truncated and endogenous forms of the protein.
What problem does this paper attempt to address?